Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839559 | 0.72 | SLC6A2 (0.50) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25235278 | 0.71 | SMN1; SMN2 (0.40) | KMT2ANPC1RAB9AMEN1HTR1A | |
| SCHEMBL25237779 | 0.71 | SMN1; SMN2 (0.40) | KMT2ANPC1RAB9AMEN1HTR1A | |
| Trifluoroacetic Acid SCHEMBL14830108 | 0.70 | SLC6A2 (0.41) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14833093 | 0.69 | HTR2C (0.50) | MAPTSLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL28839236 | 0.69 | ALDH1A1 (0.35) | — | |
| SCHEMBL31444529 | 0.67 | HTR2A (0.40) | KMT2AMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9948495 | 0.67 | CYP1A2 (0.54) | KMT2A | |
| SCHEMBL6447800 | 0.67 | TTR (0.56) | KMT2ANPC1RAB9AMAPTMEN1 | |
| SCHEMBL20319860 | 0.67 | TAAR1 (0.38) | KMT2AMAPTMEN1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535628-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210047339-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535628-B2 | Method for preparation of Asenapine | CYP3A5, QDPR, SPR | KMT2A 2211/4885NPC1 523/4885RAB9A 1014/4885 |
| US-20210047339-A1 | METHOD FOR PREPARATION OF ASENAPINE | CYP3A5, QDPR, SPR | KMT2A 2211/4885NPC1 523/4885RAB9A 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.